Elefante Mark B’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-5,370
Closed -$273K 59
2025
Q4
$273K Sell
5,370
-9,493
-64% -$485K 0.17% 52
2025
Q3
$825K Sell
14,863
-1,665
-10% -$97.5K 0.53% 36
2025
Q2
$1.14M Buy
16,528
+7,263
+78% +$494K 0.86% 30
2025
Q1
$643K Buy
9,265
+5,665
+157% +$468K 0.51% 36
2024
Q4
$310K Buy
+3,600
New +$389K 0.28% 44

Other funds holding NVO

Elefante Mark B's NVO Position: Q1 2026 in Review

Elefante Mark B sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 5,370 shares — an estimated $273K sold.

Elefante Mark B first reported a position in NVO in Q4 2024 and held it in 5 quarters. The position peaked at $1.14M in Q2 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Elefante Mark B reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Elefante Mark B sold 5,370 Novo Nordisk shares in Q1 2026, an estimated $273K.
  • Elefante Mark B first reported a position in Novo Nordisk in Q4 2024 and held it in 5 quarters.
  • Elefante Mark B's Novo Nordisk position peaked at $1.14M in Q2 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Elefante Mark B's 13F filing for Q1 2026, filed 15 May 2026.